بدائل نقل الدم توفِّر أكثر مما تكلِّف
علم الدم
Early intravenous iron administration in the Emergency Department reduces red blood cell unit transfusion, hospitalisation, re-transfusion, length of stay and costs. (يفتح نافذة جديدة)
Source: Blood Transfus 2020;18(2):106-16.
مفهرسة: PubMed 31855149
DOI: 10.2450/2019.0248-19
https://www.ncbi.nlm.nih.gov/pubmed/31855149 (يفتح نافذة جديدة)
Hemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in Europe. (يفتح نافذة جديدة)
Source: Support Care Cancer 2013;21(2):485-93.
مفهرسة: PubMed 22825456
DOI: 10.1007/s00520-012-1538-0
https://www.ncbi.nlm.nih.gov/pubmed/22825456 (يفتح نافذة جديدة)
Restrictive blood transfusion practices are associated with improved patient outcomes. (يفتح نافذة جديدة)
Source: Transfusion 2014;54(10 Pt 2):2753-9.
مفهرسة: PubMed 24995770
DOI: 10.1111/trf.12723
https://www.ncbi.nlm.nih.gov/pubmed/24995770 (يفتح نافذة جديدة)
Modeling the cost-effectiveness of prothrombin complex concentrate compared with fresh frozen plasma in emergency warfarin reversal in the United Kingdom. (يفتح نافذة جديدة)
Source: Clin Ther 2010;32(14):2478-93.
مفهرسة: PubMed 21353116
DOI: 10.1016/j.clinthera.2011.01.011
https://www.ncbi.nlm.nih.gov/pubmed/21353116 (يفتح نافذة جديدة)
Recombinant activated factor VII use in critically ill infants with active hemorrhage. (يفتح نافذة جديدة)
Source: J Pediatr Surg 2008;43(12):2235-8.
مفهرسة: PubMed 19040942
DOI: 10.1016/j.jpedsurg.2008.08.053
https://www.ncbi.nlm.nih.gov/pubmed/19040942 (يفتح نافذة جديدة)
Cost-effectiveness of eltrombopag vs intravenous immunoglobulin for the perioperative management of immune thrombocytopenia. (يفتح نافذة جديدة)
Source: Blood Adv. 2022;6(3):785-92.
مفهرسة: PubMed 34781363
DOI: 10.1182/bloodadvances.2021005627
https://pubmed.ncbi.nlm.nih.gov/34781363/ (يفتح نافذة جديدة)
Blood use in patients receiving intensive chemotherapy for acute leukemia or hematopoietic stem cell transplantation: the impact of a health system-wide patient blood management program. (يفتح نافذة جديدة)
Source: Transfusion 2017;57(9):2189-96.
مفهرسة: PubMed 28671296
DOI: 10.1111/trf.14191
https://www.ncbi.nlm.nih.gov/pubmed/28671296 (يفتح نافذة جديدة)
Impact of a conservative red blood cell transfusion strategy in children undergoing hematopoietic stem cell transplantation. (يفتح نافذة جديدة)
Source: Biol Blood Marrow Transplant 2012;18(5):813-7.
مفهرسة: PubMed 22080050
DOI: 10.1016/j.bbmt.2011.10.043
https://www.ncbi.nlm.nih.gov/pubmed/22080050 (يفتح نافذة جديدة)
The cost of blood: a study of the total cost of red blood cell transfusion in patients with β-thalassemia using time-driven activity-based costing. (يفتح نافذة جديدة)
Source: Transfusion 2019;59(11):3386-95.
مفهرسة: PubMed 31664712
DOI: 10.1111/trf.15558
https://www.ncbi.nlm.nih.gov/pubmed/31664712 (يفتح نافذة جديدة)
Implementation of a patient blood management monitoring and feedback program significantly reduces transfusions and costs. (يفتح نافذة جديدة)
Source: Transfusion 2015;55(12):2807-15.
مفهرسة: PubMed 26264557
DOI: 10.1111/trf.13260
https://www.ncbi.nlm.nih.gov/pubmed/26264557 (يفتح نافذة جديدة)
Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (يفتح نافذة جديدة)
Source: Cancer 2013;119(1):107-14.
مفهرسة: PubMed 22744794
DOI: 10.1002/cncr.27686
https://www.ncbi.nlm.nih.gov/pubmed/22744794 (يفتح نافذة جديدة)
Budget impact analysis on erythropoiesis-stimulating agents use for the management of chemotherapy-induced anaemia in Greece. (يفتح نافذة جديدة)
Source: Cost Eff Resour Alloc 2013;11(1):16.
مفهرسة: PubMed 23870502
DOI: 10.1186/1478-7547-11-16
https://www.ncbi.nlm.nih.gov/pubmed/23870502 (يفتح نافذة جديدة)
Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. (يفتح نافذة جديدة)
Source: Support Care Cancer 2012;20(1):159-65.
مفهرسة: PubMed 21359879
DOI: 10.1007/s00520-010-1083-7
https://www.ncbi.nlm.nih.gov/pubmed/21359879 (يفتح نافذة جديدة)
Comparative net cost impact of the utilization of romiplostim and intravenous immunoglobulin for the treatment of patients with immune thrombocytopenia in Québec, Canada. (يفتح نافذة جديدة)
Source: J Med Econ 2013;16(2):318-26.
مفهرسة: PubMed 23216012
DOI: 10.3111/13696998.2012.756400
https://www.ncbi.nlm.nih.gov/pubmed/23216012 (يفتح نافذة جديدة)
Blood transfusion versus hydroxyurea in beta-thalassemia in Iran: a cost-effectiveness study. (يفتح نافذة جديدة)
Source: Hematology 2018;23(7):417-22.
مفهرسة: PubMed 29157136
DOI: 10.1080/10245332.2017.1404262
https://www.ncbi.nlm.nih.gov/pubmed/29157136 (يفتح نافذة جديدة)
The burden of blood transfusion: a utilization and economic analysis--a pilot study in patients with chemotherapy-induced anemia (CIA). (يفتح نافذة جديدة)
Source: J Med Econ 2013;16(5):633-8.
مفهرسة: PubMed 23425291
DOI: 10.3111/13696998.2013.778269
https://www.ncbi.nlm.nih.gov/pubmed/23425291 (يفتح نافذة جديدة)
Prospective monitoring of plasma and platelet transfusions in a large teaching hospital results in significant cost reduction. (يفتح نافذة جديدة)
Source: Transfusion 2010;50(2):487-92.
مفهرسة: PubMed 19804569
DOI: 10.1111/j.1537-2995.2009.02413.x
https://www.ncbi.nlm.nih.gov/pubmed/19804569 (يفتح نافذة جديدة)
Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease. (يفتح نافذة جديدة)
Source: Am J Hematol 2010;85(10):795-7.
مفهرسة: PubMed 20645429
DOI: 10.1002/ajh.21772
https://www.ncbi.nlm.nih.gov/pubmed/20645429 (يفتح نافذة جديدة)
Increased hospital costs associated with red blood cell transfusion. (يفتح نافذة جديدة)
Source: Transfusion 2015;55(5):1082-9.
مفهرسة: PubMed 25488623
DOI: 10.1111/trf.12958
https://www.ncbi.nlm.nih.gov/pubmed/25488623 (يفتح نافذة جديدة)